Abstracts

Phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin/fluoropyrimidine (RAINCLOUD)

Background The RAISE study demonstrated the superiority of FOLFIRI plus ramucirumab (Ram) to FOLFIRI in second-line metastatic colorectal cancer (CRC) patients progresse...

06/27/2022

A phase II study of multiple kinase inhibitor, TT-00420, in advanced, refractory cholangiocarcinoma

Background Fibroblast growth factor (FGFR) alterations occur in 10-15% adult patients with advanced cholangiocarcinoma (CCA). Pemigatinib and Infigratinib, the first gen...

06/27/2022

A phase II study of resection followed by capecitabine plus oxaliplatin for liver metastasis of colorectal cancer (REX study): Final analysis

Background Surgical resection has been accepted as the standard therapy for colorectal cancer liver metastases (CRLM), however, high recurrence incidence even after cura...

06/27/2022

Precision oncology without biomarkers: Assessing drug sensitivity in patient-derived tumoroids to guide mCRC 3rd line therapy

Background “Precision Oncology” refers to strategies and tools to find the best treatment for a specific patient. This concept is often reduced to the combination of tar...

06/27/2022

Outcomes following FGFR inhibitor therapy in patients with cholangiocarcinoma: Multi-center single institution cohort experience

Background Cholangiocarcinomas (CCA) are a group of heterogeneous tumors arising from the biliary system. Significant sequencing efforts have provided further insights o...

Tanios Bekaii-Saab , MD, FACP;

Jennifer J. Gile ;

Vanessa Wookey ;

Tyler Zemla ;

Qian Shi ;

Nguyen Tran ;

Amit Mahipal ;

06/27/2022

Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study

Background It remains controversial regarding whether bevacizumab or anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (mAb) is the better companion ...

06/27/2022

Real-world treatments and outcomes for biliary tract cancer patients using administrative databases in Ontario, Canada

Background There is a paucity of literature on treatment patterns and outcomes in biliary tract cancer (BTC) patients in Canada. The aim of this study was to better unde...

06/27/2022

Survival outcomes of surgical resection in perihilar cholangiocarcinoma in endemic area of O. Viverrini, Thailand

Background Perihilar cholangiocarcinoma is an intractable malignancy and still remain the most challenge for surgeon. This study aims to investigate survival outcomes an...

06/27/2022

Efficacy, safety and prognostic subgroups for outcome with regorafenib in patients with refractory metastatic colorectal cancer in the real-world setting: The CORE study

Background CORRECT trial has shown a survival benefit for regorafenib over placebo in patients with metastatic colorectal cancer (mCRC) that progressed after standard th...

06/27/2022

Incidence of brain metastases in a potentially high-risk group of patients with metastatic colorectal cancer: Results from a pilot study

Background Brain metastases (BM) are an uncommon presentation of metastatic colorectal cancer (mCRC) and routine imaging of the brain is not recommended. The majority of...

06/27/2022